Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Net Income (2020 - 2025)

Historic Net Income for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to -$7.9 million.

  • Rani Therapeutics Holdings' Net Income rose 3779.28% to -$7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.6 million, marking a year-over-year increase of 1332.74%. This contributed to the annual value of -$56.6 million for FY2024, which is 1664.48% up from last year.
  • Per Rani Therapeutics Holdings' latest filing, its Net Income stood at -$7.9 million for Q3 2025, which was up 3779.28% from -$11.2 million recorded in Q2 2025.
  • Over the past 5 years, Rani Therapeutics Holdings' Net Income peaked at -$5.5 million during Q2 2021, and registered a low of -$28.7 million during Q3 2021.
  • Its 5-year average for Net Income is -$14.4 million, with a median of -$14.1 million in 2023.
  • As far as peak fluctuations go, Rani Therapeutics Holdings' Net Income plummeted by 89549.08% in 2021, and later soared by 4352.26% in 2022.
  • Quarter analysis of 5 years shows Rani Therapeutics Holdings' Net Income stood at -$13.3 million in 2021, then crashed by 30.57% to -$17.4 million in 2022, then rose by 19.09% to -$14.1 million in 2023, then decreased by 11.86% to -$15.7 million in 2024, then skyrocketed by 49.66% to -$7.9 million in 2025.
  • Its Net Income stands at -$7.9 million for Q3 2025, versus -$11.2 million for Q2 2025 and -$12.7 million for Q1 2025.